Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Up 34.3% in February

Clearside Biomedical, Inc. (NASDAQ:CLSD) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 767,400 shares, an increase of 34.3% from the February 13th total of 571,300 shares. Based on an average daily trading volume, of 258,500 shares, the short-interest ratio is currently 3.0 days. Approximately 1.1% of the company’s shares are sold short.

Wall Street Analyst Weigh In

A number of research firms recently commented on CLSD. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday, March 6th. StockNews.com raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Clearside Biomedical in a research note on Thursday, March 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.75.

Institutional Investors Weigh In On Clearside Biomedical

Hedge funds have recently bought and sold shares of the stock. Investor s Fiduciary Advisor Network LLC acquired a new stake in shares of Clearside Biomedical in the fourth quarter valued at approximately $32,000. Johnson & Johnson acquired a new position in Clearside Biomedical during the third quarter valued at approximately $105,000. Northern Trust Corp raised its position in Clearside Biomedical by 24.0% during the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock valued at $157,000 after purchasing an additional 32,048 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Clearside Biomedical by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company’s stock valued at $726,000 after purchasing an additional 32,672 shares in the last quarter. 18.75% of the stock is currently owned by institutional investors and hedge funds.

Clearside Biomedical Trading Up 7.9 %

Shares of Clearside Biomedical stock traded up $0.07 during trading hours on Tuesday, reaching $0.96. 74,509 shares of the company’s stock were exchanged, compared to its average volume of 363,538. Clearside Biomedical has a fifty-two week low of $0.77 and a fifty-two week high of $1.80. The stock has a market cap of $72.81 million, a P/E ratio of -2.13 and a beta of 2.10. The company has a 50 day moving average of $0.95 and a two-hundred day moving average of $1.05.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.